Copeptin: a neuroendocrine biomarker of COVID-19 severity

Aim: To investigate the change in a serum level of copeptin, a neuroendocrine biomarker, in differentiating grades of COVID-19 severity on admission time and to find its diagnostic potential. Materials & Methods: 160 COVID-19 patients were classified according to disease severity into 80 mild to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammad, Reham, Elshafei, Ahmed, Khidr, Emad Gamil, El-Husseiny, Ahmed A, Gomaa, Maher H, Kotb, Hend G, Eltrawy, Heba H, Farhoud, Hesham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966690/
https://www.ncbi.nlm.nih.gov/pubmed/35350852
http://dx.doi.org/10.2217/bmm-2021-1100
Descripción
Sumario:Aim: To investigate the change in a serum level of copeptin, a neuroendocrine biomarker, in differentiating grades of COVID-19 severity on admission time and to find its diagnostic potential. Materials & Methods: 160 COVID-19 patients were classified according to disease severity into 80 mild to moderate and 80 severe patients. Serum copeptin level was assessed by ELISA on their admission time. Besides, serum CRP, ferritin and D-dimer were estimated. Results: Severe COVID-19 patients showed higher serum copeptin level in comparison to mild to moderate cases, with diagnostic potential to distinguish disease severity with 93.33% sensitivity and 100% specificity at cut-off value >18.5 Pmol/l. Conclusion: Serum copeptin was remarkably increased with COVID-19 severity with reasonable differentiation potential for recently admitted patients.

Ejemplares similares